Describing the point prevalence and characteristics of venous thromboembolism in patients with thrombotic thrombocytopenic purpura

J Thromb Haemost. 2020 Nov;18(11):2870-2877. doi: 10.1111/jth.15027. Epub 2020 Aug 27.

Abstract

Background: Arterial thromboembolic events are relatively common and well-described in patients with thrombotic thrombocytopenic purpura (TTP). However, the literature describing venous thromboembolism (VTE) in TTP is scarce.

Methods: Single-institution retrospective chart review was conducted in TTP patients over a 10-year period to describe the point prevalence of VTE. Data were analyzed using descriptive statistics.

Results: We identified 77 consecutive patients with 123 episodes of TTP. Of these patients, 14 (18%) experienced 16 VTEs (6 pulmonary embolisms, 6 deep vein thromboses, 4 superficial vein thromboses [SVT]). Excluding SVT, the point prevalence of VTE was 14%. All were acute and associated with admission for acute TTP. All patients were treated with plasma exchange (PLEX); 6/8 patients on concurrent PLEX at VTE diagnosis were exchanged with solvent-detergent plasma (SDP). Platelet and lactate dehydrogenase levels at time of VTE diagnosis had largely normalized from presentation values (median 175 × 109 U/L [interquartile range 130.75, 250] and 232 U/L [interquartile range 178.75, 263.5], respectively). Most VTEs (9/16) occurred while patients were not on pharmacologic thromboprophylaxis. All but one VTE was treated with anticoagulation. No VTEs were fatal or massive.

Conclusions: Our data provide additional evidence that TTP patients may be at risk for VTE. It is possible that SDP exerted a prothrombotic effect. TTP-associated VTEs may be pathophysiologically distinct from arterial thromboses because they occur following hematological recovery. VTE thromboprophylaxis was not commonly used. Our findings suggest the need to implement VTE thromboprophylaxis earlier in hospitalized patients with TTP.

Keywords: blood platelets; plasma exchange; thrombosis; thrombotic thrombocytopenic purpura; venous thromboembolism.

MeSH terms

  • Anticoagulants
  • Humans
  • Prevalence
  • Purpura, Thrombotic Thrombocytopenic* / diagnosis
  • Purpura, Thrombotic Thrombocytopenic* / epidemiology
  • Purpura, Thrombotic Thrombocytopenic* / therapy
  • Retrospective Studies
  • Venous Thromboembolism* / diagnosis
  • Venous Thromboembolism* / epidemiology

Substances

  • Anticoagulants